Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 8, Number 3—March 2002
Dispatch

Recent Increase in Meningitis Caused by Neisseria meningitidis Serogroups A and W135, Yaoundé, Cameroon

Tables
Article Metrics
44
citations of this article
EID Journal Metrics on Scopus
Marie-Christine Fonkoua*, Muhamed-Kheir Taha†, Pierre Nicolas‡, Patrick Cunin*, Jean-Michel Alonso†, Raymond Bercion*, Jeanne Musi*, and Paul M.V. Martin*Comments to Author 
Author affiliations: *Centre Pasteur du Cameroun, Yaoundé, Cameroun; †Institut Pasteur, Paris, France; ‡Centre Collaborateur de l’OMS, Institut de Médecine Tropicale du Service de Santé des Armées, Marseille, France;

Cite This Article

Abstract

From 1991 to 1998, Neisseria meningitidis serogroups A, B, and C represented 2%-10% of strains isolated from cases of bacterial meningitis in Yaoundé. During 1999 to 2000, the percentage of meningococci reached 17%, a proportion never reported since recordkeeping began in 1984. The increase of serogroup A meningococci and the emergence of W135 strains highlight the need for increased surveillance for better diagnosis and prevention.

Neisseria meningitidis serogroup A causes major epidemics of meningitis in Africa, essentially within the African meningitis belt (1). Epidemics of cerebrospinal meningitis in this belt are often enormous (1). During the first 9 months of 1996 in the World Health Organization (WHO) African Region, 146,166 cases were reported to WHO; 15,783 were fatal. During that year, 42,129 cases occurred in Burkina Faso, 7,244 in Mali, 16,050 in Niger, and 75,069 in Nigeria. These four countries reported 95% of the cases in Africa in 1996, for an overall case-fatality rate of 10.6% (2).

The recommended control practices in Africa involve vaccination with the meningococcal bivalent polysaccharide A/C vaccine in response to epidemics. Efficient public health practice necessitates that epidemics be detected early, stocks of vaccines be set up in target regions, and field vaccination with the bivalent vaccine be rapid, since the quadrivalent ACYW135 vaccine has limited worldwide supply and is more expensive.

The presence of N. meningitidis serogroup W135 has been confirmed in Africa for some time. In Burkina Faso in 1980, 1.3% of the meningococcal strains isolated from rhinopharyngeal carriers belonged to serogroup W135. In 1981 and 1982, monitoring of the serogroups responsible for meningococcal meningitis at Dakar (Senegal) and Niamey (Niger) showed that 4% and 3% of strains, respectively, belonged to serogroup W135 (3). In 1984 and 1985, 7% of N. meningitidis strains isolated from meningitis cases in Gambia belonged to serogroup W135 (4). In 1993 and 1994, two strains of N. meningitidis W135 were isolated from patients in Mali; both belonged to the ET-37 complex (5). More recently, in 1994, six strains of serogroup W135 isolated from clinical cases in Gambia were studied; they also belonged to the ET-37 complex. DNA macrorestriction analysis of these strains identified four different profiles in pulsed-field gel electrophoresis (PFGE), indicating that the strains involved were closely related but different (6). W135 strains are often isolated after intensive campaigns of vaccination against meningococci of serogroups A and C (3,4,6).

In spring 2000, an epidemic of N. meningitidis W135 infection broke out among Hajj pilgrims (for whom vaccination against meningococci of serogroups A and C is mandatory) and their close contacts. In all, 241 cases were reported in Saudi Arabia and 90 in 13 other countries (7), including the United States (4 cases) (8), the United Kingdom (33 cases), and France (19 cases). All these strains showed markers of the ET-37 complex; had an antigenic formula W135:2a:P1-5,2; a sequence type ST-11; and the same profile on PFGE (9), confirming the clonal origin of the epidemic. Four W135 strains isolated in U.S. patients epidemiologically linked to Hajj pilgrims were further studied. The sequence of the porA gene showed that these four strains had variable regions VR1 and VR2 identical to those of the prototype P1.5,2 strain (8).

Apparently, the W135 strains isolated in Africa until 1995 did not cause large epidemics, even if isolated in the countries in the African meningitis belt in which epidemics due to serogroups A meningococci are frequent (e.g., Niger, Mali, Senegal, and Gambia). In Niger in 1981, only one W135 strain of 231 meningococci was isolated from a meningitis case (3). Similarly, W135 accounted for 7 of 42 strains in 1982 in Niger, and 3 of 76 strains in Senegal in 1981 to 1982 (3), 3 of 41 in Guinea in 1984 to 1985 (4), and 2 of 75 strains isolated in 1991 to 1994 in six countries in the African meningitis belt (5). However, available information shows that the case-fatality rate due to W135 strains was relatively high in Africa before 1995, as in Europe during the recent Hajj 2000 epidemic: 6 (35%) of 17 cases in Africa before 1995 (in Senegal, Gambia, and Niger) and 10 (18%) of 56 cases in Europe in 2000 (in the United Kingdom, France, and the Netherlands).

The Study

We report here a sudden increase in the number of meningococcal strains isolated from cerebrospinal fluid (CSF) sent to the Medical Biology Laboratory of the Pasteur Centre of Cameroon (CPC) at Yaoundé in the 1-year period 1999 to 2000 (note that in Cameroon the administrative year begins on July 1). Yaoundé, the capital of Cameroon, is a city of approximately 1,500,000 inhabitants. Located in the forest zone at an altitude of 750 m, about 400 km south of the southern limit of the African meningitis belt, it has a humid, tropical climate. The CPC laboratory receives samples from patients admitted to the principal hospitals of Yaounde and, in 1999 to 2000, 91.5% of CSF samples sent to the laboratory were from children <15 years old; 81% were from children <5 years.

From 1984 to 1990, bacteria were isolated from 767 (5.8%) of 13,134 CSF samples; 42 (5.5%) of these were N. meningitidis. This proportion was significantly lower than during the 1991 to 2000 period (8.7%; p<0.05). We do not know if there were changes in the population of patients using the CPC services that might account for the slow increase in cases of meningococcal disease. Slow improvement of laboratory practices and medical competence might account for slowly increasing proportions of N. meningitidis over a 20-year period. However, no major changes in laboratory techniques occurred in 1999 at CPC that could account for the sudden increase observed in 1999 and 2000. Moreover, during that 20-year period, most CSF samples came from the same pediatric wards of the neighboring Central Hospital of Yaoundé and other major children’s hospitals.

The table shows the changes in isolation rates of N. meningitidis from clinical cases at Yaoundé during 1991-92 to 2000-01. The number of meningococcal strains isolated has remained small for the last 10 years, as would be expected in a zone located at a considerable distance south of the African meningitis belt and one in which pneumococci and Haemophilus influenzae are the two most frequent bacterial agents of meningitis. Most meningococcal strains isolated were serogroup A, the most frequent group in Africa. The proportion of meningococci identified in cases of bacterial meningitis varied significantly in this period (p<0.01).

In the 2-year period 1998 to 2000, two events occurred. The first was an increase in the number of isolates of N. meningitidis; such isolates accounted for >19% of strains isolated from cases of bacterial meningitis in 1999 to 2000, and 21% in 2000 to 2001—two to three times more than normal. We checked records back to 1984 and found that in none of the years in this period was such a large number of meningococci isolated at Yaoundé. The second noteworthy event was the appearance of serogroup W135 strains, which accounted for 9 (19%) of 48 meningococcal strains isolated in 1998 to 2000 versus 0 of 46 in 1991 to 1997 (p<0.01).

One W135 case occurred in January 1999 in a 12-year-old boy from Yaoundé who had no known contact with a Hajj pilgrim and no recent history of travel. On the four W135 patients from 1999 to 2000, one was male and three were female. Ages were 2, 3, 29, and 37 years. Onsets of disease were in July 1999 and in May and June 2000, i.e., after the usual meningococcal peak in the dry season, and none had known direct or indirect contact with each other or with a Hajj pilgrim. In 2000 to 2001, four cases occurred, all in males (aged 9, 15, 23, and 40 years); onsets of diseases occurred in January 2001, then in March, May, and June. One of them was in a 23-year-old student, who had been studying in Dakar (Senegal) for 2 years; he became ill while observing holy days in Cameroon. He could have been in indirect contact with Hajj pilgrims, since he was Muslim and Senegal is largely Muslim. Vaccination status was obtained for five of these nine patients: two were vaccinated against meningococcal meningitis, including the student.

The five strains of N. meningitidis W135 isolated in 1999 to 2000 were serotyped, subtyped, and studied by molecular biology techniques. All belonged to the ET-37 complex and had the antigenic formula W135:2a:P1.2,5. Two strains were subjected to multilocus sequence typing; both were of sequence type ST-11, typical of isolates of the ET-37 complex (10). These five strains were indistinguishable by multilocus DNA fingerprinting and showed markers of E-37 complex (11). Finally, SpeI restriction profiles were determined by PFGE: four of the strains were indistinguishable, and the final strain differed by one band only. All these clones differed slightly (by two bands for four isolates and by three bands for one isolate) from the clone isolated from the Hajj pilgrims in 2000.

Conclusions

These results show an increase of serogroup A meningococci in Yaoundé and demonstrate the presence and circulation of at least one indigenous clone of N. meningitidis W135 of the ET-37 complex in Central Africa. The clone is very similar to, but differs slightly from, the clone responsible for a meningitis outbreak among Hajj pilgrims in 2000 (8,9). Since none of the patients with W135 meningococci had direct contact with Hajj pilgrims and Cameroonian W135 strains are slightly different by PFGE from the W135 clone isolated in Europe and the United States in 2000, these strains from Cameroon seem to predate the 2000 Hajj-associated outbreak. A larger study of the W135 strains isolated in Africa, Europe, and Asia, from patients with no direct link to the pilgrimage to Mecca (indigenous strains) would make it possible to identify the geographic origin of the strain responsible for the Mecca epidemic in 2000. Such studies would also make it possible to elucidate the role of A and C vaccination in the selection of W135 clones belonging to the ET-37 complex.

We cannot explain with certainty why serogroup A meningococci has increased in Yaoundé, but the finding stresses the importance of continuous surveillance. The circulation of W135 strains in Central Africa raises questions about their epidemic potential and highlights the microbiologic surveillance of meningococcal meningitis. Thus, anti-W135 serogrouping antibodies are necessary for all National Reference Laboratory services. Antigen-detection kits for the diagnosis of meningitis should also contain anti-W135 antibodies. Moreover, the problem of the availability of a quadrivalent vaccine, including the W135 antigen, should be resolved. Strengthening the capacities for epidemiologic and microbiologic surveillance of meningitis in Africa is a prerequisite for prevention and control of meningococcal epidemics.

Marie-Christine Fonkoua is a senior medical microbiologist at the Centre Pasteur in Cameroon. Her interests focus on the microbiologic surveillance of bacterial meningitis and sexually transmitted diseases, and antibiotic resistance.

Top

References

  1. Greenwood  BM. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg. 1999;93:34153. DOIPubMed
  2. World Health Organization. Cerebrospinal meningitis in Africa. Wkly Epidemiol Rec. 1996;41:3112.
  3. Denis  F, Rey  JL, Amadou  A, Saliou  P, Prince-David  M, M’Boup  S, Emergence of meningococcal meningitis caused by W135 serogroup in Africa. Lancet. 1982;2:13356. DOIPubMed
  4. Greenwood  BM, Smith  AW, Hassan-King  M, Bijlmer  HA, Shenton  FC. The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in the Gambia, West Africa. Trans R Soc Trop Med Hyg. 1986;80:10067. DOIPubMed
  5. Guibourdenche  M, Hoiby  EA, Riou  JY, Varaine  F, Joguet  C, Caugant  DA. Epidemics of serogroup A Neisseria meningitidis of subgroup III in Africa, 1989-1994. Epidemiol Infect. 1996;116:11520.PubMed
  6. Kwara  A, Adegbola  RA, Corrah  PT, Weber  M, Achtman  M, Morelli  G, Meningitis caused by a serogroup W135 clone of the ET-37 complex of NM in West Africa. Trop Med Int Health. 1998;3:7426.PubMed
  7. Nicolas  P, Popovic  T, Caugant  D. Meningococcal disease, serogroup W135—update. communicable disease surveillance and response. Available at: URL: http://www.who.int/disease-outbreak-news/n2000/may/12may2000.html
  8. Popovic  T, Sacchi  CT, Reeves  MW, Whitney  AM, Mayer  LW, Noble  CA, Neisseria meningitidis serogroup W135 isolates associated with the ET-37 complex. Emerg Infect Dis. 2000;6:4289.PubMed
  9. Taha  MK, Achtman  M, Alonso  JM, Greenwood  B, Ramsay  M, Fox  A, Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet. 2000;356:2159. DOIPubMed
  10. Maiden  MC, Bygraves  JA, Feil  E, Morelli  G, Russel  JE, Urwin  R, Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A. 1998;95:31405. DOIPubMed
  11. Kriz  P, Giorgini  D, Musilek  M, Larribe  M, Taha  MK. Microevolution through DNA exchange among strains of Neisseria meningitidis isolated during an outbreak in the Czech Republic. Res Microbiol. 1999;150:27380. DOIPubMed

Top

Table

Top

Cite This Article

DOI: 10.3201/eid0803.010308

Table of Contents – Volume 8, Number 3—March 2002

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Paul Martin, Institut Pasteur, 25, rue du Dr Roux, 75724 Paris Cedex 15, France; fax: 33-01-40-61-35-67;

Send To

10000 character(s) remaining.

Top

Page created: July 15, 2010
Page updated: July 15, 2010
Page reviewed: July 15, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external